Novo CEO Lars Fruergaard Jørgensen hopes for Eli Lilly's future success

US firm Eli Lilly will hopefully keep up its great performance in the lucrative GLP-1 market, says Novo Nordisk CEO Lars Fruergaard Jørgensen.
Novo Nordisk CEO Lars Fruergaard Jørgensen | Photo: Stine Bidstrup/ERH
Novo Nordisk CEO Lars Fruergaard Jørgensen | Photo: Stine Bidstrup/ERH
BY BENJAMIN WERNER CHRISTENSEN, TRANSLATED BY NIELSINE NIELSEN

We love it the way it is right now, and for this reason, we would love it if things continued in the same way. This sentiment captures the mindset of Danish pharmaceutical firm Novo Nordisk's CEO Lars Fruergaard Jørgensen.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading